Bausch Health Companies Inc(BHC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BHC Bausch Health Companies Inc

Closed 12-23 16:00:00 EST

7.48

+0.01

+0.13%

盘后7.49

+0.01+0.13%

19:38 EST

High7.52	Low7.41	Vol873.26K
Open7.41	D1 Closing7.47	Amplitude1.47%
Mkt Cap2.75B	Tradable Cap2.04B	Total Shares367.80M
T/O6.52M	T/O Rate0.32%	Tradable Shares273.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BHC","market":"US","secType":"STK","nameCN":"Bausch Health Companies Inc","latestPrice":7.48,"timestamp":1734987600000,"preClose":7.47,"halted":0,"volume":873259,"hourTrading":{"tag":"盘后","latestPrice":7.49,"preClose":7.48,"latestTime":"19:38 EST","volume":94997,"amount":709301.974462,"timestamp":1735000702059},"delay":0,"floatShares":273172588,"shares":367803401,"eps":-0.484617,"marketStatus":"Closed","change":0.01,"latestTime":"12-23 16:00:00 EST","open":7.41,"high":7.52,"low":7.41,"amount":6520416.7680544,"amplitude":0.014726,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.484617,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735030800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":7.47,"preHourTrading":{"tag":"盘前","latestPrice":7.45,"preClose":7.47,"latestTime":"08:31 EST","volume":4413,"amount":32674.408037999998,"timestamp":1734960678208},"postHourTrading":{"tag":"盘后","latestPrice":7.49,"preClose":7.48,"latestTime":"19:38 EST","volume":94997,"amount":709301.974462,"timestamp":1735000702059},"volumeRatio":0.834119,"impliedVol":0.7288,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/BHC","defaultTab":"news","newsList":[{"id":"2492911053","title":"Is Bausch Health Companies (BHC) Among Billionaire Paul Singer’s Top Long-Term Stock Picks?","url":"https://stock-news.laohu8.com/highlight/detail?id=2492911053","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492911053?lang=en_us&edition=fundamental","pubTime":"2024-12-19 14:49","pubTimestamp":1734590957,"startTime":"0","endTime":"0","summary":"We recently published a list of Billionaire Paul Singer’s Top 12 Long-Term Stock Picks. In this article, we are going to take a look at where Bausch Health Companies Inc.  stands against other Billionaire Paul Singer’s long-term stock picks.The world’s “most feared investor,” Paul Singer, needs no introduction. He has built a reputation on Wall Street for his aggressive and litigious tactics that often generate significant shareholder value. While the 79-year-old billionaire investor is not as flashy or public as other activist investors, he has built a reputation for exploiting weaknesses in various asset classes.Singer’s initial approach to investing was to target companies and even governments while purchasing extremely distressed debt. Therefore, he is best known as a “vulture capitalist” as a result of this tactic. Since then, he has diversified into a number of investment strategies, such as activist investing, portfolio management, and commodity trading.In addition to the high i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GFHY2ZSLDsd.3mLt8IX0bA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/dc66899538c4a6dfed6ec0cda0994f1b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GFHY2ZSLDsd.3mLt8IX0bA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/dc66899538c4a6dfed6ec0cda0994f1b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-companies-bhc-among-064917824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BLCO","BHC","BK4007","BK4198"],"gpt_icon":0},{"id":"2490388224","title":"Bausch Says Potential Sale of Bausch + Lomb Still On Table","url":"https://stock-news.laohu8.com/highlight/detail?id=2490388224","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490388224?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:05","pubTimestamp":1734008700,"startTime":"0","endTime":"0","summary":"Bausch Health said a potential sale of its subsidiary Bausch + Lomb is still on the table following a report that one suitor might back out of a joint bid to acquire the eye-health company.The Canadian pharmaceutical company said Thursday that it was confirming the potential sale process at the behest of Canadian regulators in light of recent stock volatility related to market rumors.Bausch seemed to be referencing a report from the Financial Times on Wednesday that Blackstone was balking at the high price being sought for Bausch + Lomb. It previously teamed up with investor TPG to explore a bid for the subsidiary company, of which Bausch owns 88%.Bausch said it still believes a full separation of the subsidiary \"makes strategic sense\" and that a potential sale is one of several options being considered.In October, Bausch rejected debt-restructuring proposals from bondholders aimed at staving off bankruptcy and pivoted to exploring a sale of its Bausch + Lomb stake that could pay off c","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2490800177","title":"Bausch Health Says Bausch + Lomb Subsidiary Sale Under Consideration","url":"https://stock-news.laohu8.com/highlight/detail?id=2490800177","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490800177?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:50","pubTimestamp":1734007828,"startTime":"0","endTime":"0","summary":"Bausch Health  said Thursday that it has authorized its Bausch + Lomb  subsidiary to explore a potential sale, among the options under consideration to complete a previously announced plan to separate the two companies.\"The company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation makes strategic sense,\" Bausch said in a statement requested by the Canadian Investment Regulatory Organization. \"That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.\"Bausch Health, which trades on both the New York and Toronto stock exchanges, said it does not intend to provide additional detail unless necessary.Bausch Health shares were 1.6% higher in US premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4198","BLCO","BHC"],"gpt_icon":0},{"id":"2490807204","title":"Bausch Health says Bausch + Lomb sale exploration process ‘ongoing’","url":"https://stock-news.laohu8.com/highlight/detail?id=2490807204","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490807204?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:26","pubTimestamp":1734006391,"startTime":"0","endTime":"0","summary":"Bausch Health Companies (BHC) issued the following statement in response to a request from the Canadian Investment Regulatory Organization: “As pre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bausch-health-says-bausch-lomb-sale-exploration-process-ongoing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bausch-health-says-bausch-lomb-sale-exploration-process-ongoing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2490807893","title":"Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb","url":"https://stock-news.laohu8.com/highlight/detail?id=2490807893","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490807893?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:00","pubTimestamp":1734004800,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc.  , a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization :. \"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation  , makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZQDRwZbk7e2x5CBa0PQYBQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/b4b473854786a5e338a20a4140a4d2c6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZQDRwZbk7e2x5CBa0PQYBQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/b4b473854786a5e338a20a4140a4d2c6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-responds-rumors-potential-120000336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2490893816","title":"TSX Closer: The Market Surges as the Bank of Canada Makes Its Jumbo Cut, Further Cuts Predicted","url":"https://stock-news.laohu8.com/highlight/detail?id=2490893816","media":"MT Newswires","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490893816?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:33","pubTimestamp":1733952813,"startTime":"0","endTime":"0","summary":"Canada's largest stock market, the Toronto Stock Exchange closed higher on Wednesday, climbing after the Bank of Canada, as expected, cut its benchmark interest rate by 50 basis points with more cuts expected to come.The S&P/TSX Composite Index closed up 153.37 points to 25,657.7. The Information Technology, and Energy sectors both closed up 1.4%, leading all sectors, while Health Care, down 3%, was the biggest decliner.The Bank of Canada cut interest rates by half of a percentage point on Wednesday, meeting widespread expectations, but not every economist welcomed the move. Derek Holt, Scotiabank's Head of Capital Markets Economics, said \"It almost had the feel of having an apology note attached to the decision\".Holt last week warned the central bank is misreading the job market and announcing a 50 basis cut, as it did, risks overheating conditions for the bulk of the economy.Gold futures rose for a fourth-straight day late afternoon on Wednesday as a key U.S. inflation measure met ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tsx-closer-market-surges-bank-213333660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007","WTI","BK4213"],"gpt_icon":0},{"id":"2490389333","title":"Bausch + Lomb Shares Down on Report That Potential Buyer May Back Out","url":"https://stock-news.laohu8.com/highlight/detail?id=2490389333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490389333?lang=en_us&edition=fundamental","pubTime":"2024-12-12 01:32","pubTimestamp":1733938320,"startTime":"0","endTime":"0","summary":"Shares of Bausch Health and subsidiary Bausch + Lomb fell sharply Wednesday after a report by the Financial Times suggested that Blackstone might back out of a joint bid to acquire the eye-health business.Shares of parent company Bausch Health traded 8.8% lower at 10.76 Canadian dollars , while Bausch + Lomb shares fell 14% to C$25.11.According to unidentified sources, the private-equity firm teamed up with investor TPG to explore a bid for Bausch + Lomb in October but Blackstone had subsequently balked at the high price the seller was expected.Bausch + Lomb makes a variety of eye-related products including contact lenses, ophthalmic pharmaceuticals and ophthalmic surgical devices.Earlier in October, Bausch Health rejected debt-restructuring proposals from bondholders, pivoting instead on exploring a sale of its 88% stake in Bausch + Lomb worth potentially billions of dollars which it could use to pay creditors and reward shareholders, The Wall Street Journal had reported.Solvency is a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2490896930","title":"TSX up 105 Points at Midday, With Info Tech, Energy, Higher; Healthcare The Biggest Decliner","url":"https://stock-news.laohu8.com/highlight/detail?id=2490896930","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490896930?lang=en_us&edition=fundamental","pubTime":"2024-12-12 01:22","pubTimestamp":1733937766,"startTime":"0","endTime":"0","summary":"The Toronto Stock Exchange is up 105 points with info tech  and energy , the sole gainers.Elsewhere, CIBC noted the U.S. November inflation report showed \"continued stickiness\" in price pressures. Core CPI prices rose 0.31% m/m in the month, in line with consensus expectations. Three-month annualized core CPI rose by one tick to 3.7% in November. Headline inflation came in at 0.3% m/m in the month, also in line with forecasters' predictions. In year-over-year terms, headline inflation rose by one tick to 2.7%, while core was unchanged at 3.3%. It said: \"Today's report won't prevent the Fed from cutting by 25bps later this month, especially with the labor market showing a clear cooling trend. But the threat of a pause and a stretched out easing cycle is growing if growth doesn't slow or aggregate price pressures don't cool a bit more.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tsx-105-points-midday-tech-172246609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","US12M.BOND","PCOM","BK4122","HCSG","US3Y.BOND","US10Y.BOND","US2Y.BOND","BHC","US5Y.BOND","US7Y.BOND","BK4007","US30Y.BOND","US6M.BOND"],"gpt_icon":0},{"id":"2490898879","title":"Bausch Health falls -9.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490898879","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490898879?lang=en_us&edition=fundamental","pubTime":"2024-12-12 01:05","pubTimestamp":1733936752,"startTime":"0","endTime":"0","summary":"Bausch Health (BHC) is down -9.8%, or -81c to $7.50. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bausch-health-falls-9-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bausch-health-falls-9-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2490867996","title":"Bausch + Lomb down after report that Blackstone could back away from takeover bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2490867996","media":"Investing.com","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490867996?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:08","pubTimestamp":1733933311,"startTime":"0","endTime":"0","summary":"Investing.com --Bausch + Lomb Corp shares tumbled more than 12% on Wednesday in New York Stock Exchange after report that Blackstone  could back away from a joint bid to acquire the eyecare company, raising doubts about one of the largest healthcare buyouts of the year.The private equity giant had teamed up with investor TPG in October to explore a bid for Bausch + Lomb . However, Financial Times reported citing sources that Blackstone has grown wary of the seller’s high price expectations.Citi downgraded Bausch + Lomb to “neutral” from “buy” in a note on Wednesday, slashing its price target to $22 from $24.The auction process for Bausch + Lomb, known for its contact lenses, dry eye treatments, and surgical ophthalmology devices, began earlier this year as its debt-laden parent, Bausch Health, seeks to reduce its liabilities.Albertsons demands billions from rival Kroger after terminating merger bid. Global shares, US dollar rise as inflation data reinforces Fed hopes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-lomb-down-report-blackstone-160831507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4452.SGD","BK4588","IE00BLSP4239.USD","IE00BN8TJ469.HKD","BK4135","BK4585","BX","IE00B64PRP62.GBP","IE0004445239.USD","IE00B3QW5Z07.USD","IE00BBT3K403.USD","BK4007","BLCO","IE00BGHQF748.EUR","BK4198","BHC"],"gpt_icon":0},{"id":"2490001145","title":"Why Is Bausch Health Companies Inc. (BHC) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490001145","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490001145?lang=en_us&edition=fundamental","pubTime":"2024-12-11 12:00","pubTimestamp":1733889626,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now.In this article, we are going to take a look at where Bausch Health Companies Inc.  stands against the other cosmetic surgery and aesthetics stocks.In the face of economic uncertainty, consumer preferences in the beauty industry are changing. A Bloomberg Intelligence poll conducted in June 2024 with 650 participants found that 40% of respondents gave beauty and personal care purchases more importance than other products. Nonetheless, this represents the lowest result since the survey's launch two years ago, a 10-percentage-point drop from January.In one of the recent developments, finance solutions like \"buy-now, pay-later\" loans are being given to make cosmetic procedures more affordable because of the rising demand for these procedures in the United States, as reported by Bloomberg. While the demand spike from the pandemic has subsided, rates of aesthetic procedures are still substantia","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GFHY2ZSLDsd.3mLt8IX0bA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/dc66899538c4a6dfed6ec0cda0994f1b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GFHY2ZSLDsd.3mLt8IX0bA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/dc66899538c4a6dfed6ec0cda0994f1b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-bausch-health-companies-inc-040026706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC","BK4007"],"gpt_icon":0},{"id":"2489480457","title":"Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2489480457","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489480457?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:00","pubTimestamp":1733403600,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc.  and its gastroenterology  business, Salix Pharmaceuticals , alongside the U.S. Pain Foundation , the International Foundation for Gastrointestinal Disorders , and the American Chronic Pain Association  have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation  Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC.\"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day,\" said Kathy Sapp, CEO of ACPA. \"By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful differenc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZQDRwZbk7e2x5CBa0PQYBQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/b4b473854786a5e338a20a4140a4d2c6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZQDRwZbk7e2x5CBa0PQYBQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/b4b473854786a5e338a20a4140a4d2c6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-salix-collaboration-health-130000233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2488679598","title":"Bausch Health Taps Jonathan Sadeh as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2488679598","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488679598?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:27","pubTimestamp":1733146020,"startTime":"0","endTime":"0","summary":"Bausch Health has named former Bristol-Meyers Squibb executive Jonathan Sadeh to head up its research and development.Sadeh joins the Canadian pharmaceutical company as executive vice president, chief medical officer and head of R&D. In the role, he will oversee Bausch's entire R&D process, working with the company's scientists and engineers.Sadeh has more than two decades clinical research and drug development experience as a physician-scientist and pharma-industry leader, Bausch said. Most recently at Bristol-Meyers Squibb he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles, including senior vice president and global programs head for immunology, cardiovascular and neuroscience, immunology therapeutic area head.The Laval, Quebec, company in late October said it was targeting revenue this year of between $9.5 billion and $9.68 billion. Bausch has rejected debt-restructuring proposals from bondholders as it continues to explore ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1585245621.USD","IE0009355771.USD","LU0225284248.USD","IE00BJT1NW94.SGD","LU0225771236.USD","LU1074936037.SGD","LU0096364046.USD","LU0114720955.EUR","LU0061475181.USD","BK4532","IE00BJJMRZ35.SGD","LU1868836757.USD","LU1868836914.USD","LU1868837136.USD","LU1868836591.USD","LU1670710588.SGD","LU1868837300.USD","LU2242646821.SGD","LU0882574055.USD","LU1291159041.SGD","BK4581","LU1670711123.USD","LU1032466523.USD","LU1670711040.USD","LU2125154935.USD","LU2242652126.USD","LU1093756168.USD","LU1093756325.SGD","BHC","LU1430594728.SGD","LU2133065610.SGD","LU0456855351.SGD","IE00BSNM7G36.USD","LU0985481810.HKD","LU2360032135.SGD","LU1989771016.USD","LU2125154778.USD","LU0868494617.USD","BK4559","IE00B2B36J28.USD","BMY","IE00BFTCPJ56.SGD","BK4534","LU1670710661.SGD","LU1718418525.SGD","LU0306806265.USD","LU0237698245.USD","LU0321505439.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"2488684579","title":"Bausch Health Appoints New Chief Medical Officer and Head of R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2488684579","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488684579?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc.  is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb, he was responsible for multiple drug approvals in dermatology and gastroenterology and held several key roles including Senior Vice President and Global Programs Head for Immunology, Cardiovascular and Neuroscience, Immunology Therapeutic Area Head, as well as the China R&D Head. Jonathan received a master's degree i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZQDRwZbk7e2x5CBa0PQYBQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/b4b473854786a5e338a20a4140a4d2c6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZQDRwZbk7e2x5CBa0PQYBQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/b4b473854786a5e338a20a4140a4d2c6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-appoints-chief-medical-130000657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2487522597","title":"Why Bausch Health Companies (BHC) is One of the Best Canadian Stocks to Buy Under $10?","url":"https://stock-news.laohu8.com/highlight/detail?id=2487522597","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487522597?lang=en_us&edition=fundamental","pubTime":"2024-11-30 17:14","pubTimestamp":1732958082,"startTime":"0","endTime":"0","summary":"We recently published a list of the 10 Best Canadian Stocks to Buy Under $10. In this article, we are going to take a look at why Bausch Health Companies Inc.  is one of the best Canadian stocks to buy under $10.The Canadian stock market had a positive third quarter, following a sluggish start earlier in 2024. The market was driven by domestic rate cuts and rebounding global markets. The BMO S&P 500 Index ETF, iShares Core S&P/TSX Capped Composite Index ETF, and iShares S&P/TSX 60 Index ET have surged over 33%, 20%, and 22% year-to-date, as of November 27.With that, let’s take a look at where Bausch Health Companies Inc.  ranks among the best Canadian stocks to buy under $10.Bausch Health Companies Inc. , based out of Laval, Quebec, Canada, is a global di","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VW9Tx2PkgN2vwHlMdikU9w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/95f75cddb7f5d59b695b5ea0ca3e5c49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VW9Tx2PkgN2vwHlMdikU9w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/95f75cddb7f5d59b695b5ea0ca3e5c49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-bausch-health-companies-bhc-091442505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2487527595","title":"Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report?","url":"https://stock-news.laohu8.com/highlight/detail?id=2487527595","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487527595?lang=en_us&edition=fundamental","pubTime":"2024-11-30 00:31","pubTimestamp":1732897905,"startTime":"0","endTime":"0","summary":"A month has gone by since the last earnings report for Bausch Health . Shares have lost about 11.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales. Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. The reported figure increased from $1.03 in the year-ago quarter due to higher revenues.Total revenues of $2.5 billion were up 12% year over year. The top line also beat the Zacks Consensus Estimate of $2.4 billion.Excluding the impact of $9 million in foreign exchange, $96 million in acquisitions, and $16 million in divestitures and discontinuations, revenues increased 9% organically.Salix revenues t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YliGu3uiWo7T6YkWQuaEpA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YliGu3uiWo7T6YkWQuaEpA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-bausch-bhc-down-11-163145747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC"],"gpt_icon":0},{"id":"2486318170","title":"Bausch Health Companies Inc. (NYSE:BHC) is favoured by institutional owners who hold 56% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2486318170","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486318170?lang=en_us&edition=fundamental","pubTime":"2024-11-28 19:47","pubTimestamp":1732794469,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Bausch Health Companies implies that they have significant influence over the company's share price. Every investor in Bausch Health Companies Inc.  should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 56% ownership. Put another way, the group faces the maximum upside potential .Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future.Let's delve deeper into each type of owner of Bausch Health Companies, beginning with the chart below.View our latest analysis for Bausch Health Companies. What Does The Institutional Ownership Tell Us About Bausch Health Companies?Many institutions measure their performance against an index that approximates","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-health-companies-inc-nyse-114749286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NYSE","BHC","BK4007"],"gpt_icon":0},{"id":"2486165880","title":"Bausch Health put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2486165880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486165880?lang=en_us&edition=fundamental","pubTime":"2024-11-27 02:20","pubTimestamp":1732645236,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Bausch Health (BHC) with 20,171 puts trading, or 8x expected. Most active are Dec-24 7 puts and Dec-24 7.5 puts, with total v...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bausch-health-put-volume-heavy-and-directionally-bearish-15?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bausch-health-put-volume-heavy-and-directionally-bearish-15?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BHC"],"gpt_icon":0},{"id":"2486373059","title":"Bausch (BHC) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2486373059","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486373059?lang=en_us&edition=fundamental","pubTime":"2024-11-26 01:00","pubTimestamp":1732554012,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Bausch Health , as it has been recently upgraded to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for Bausch is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.For th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-bhc-upgraded-buy-heres-170012621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BHC"],"gpt_icon":0},{"id":"2485213211","title":"Bausch & Lomb Corporation (BLCO)-A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2485213211","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485213211?lang=en_us&edition=fundamental","pubTime":"2024-11-23 03:31","pubTimestamp":1732303903,"startTime":"0","endTime":"0","summary":"In this article, we’ll summarize a bullish thesis posted on VIC covering Bausch & Lomb Corporation  in late July when BLCO stock was trading at $15.83. Currently, BLCO stock is trading at $19.68, which is near its 52-week high of $21.69. So, BLCO stock has gained over 24% since the publication of this thesis. BLCO stock’s forward PE ratio  is at 32.26, and the stock is trading at 1.48 times, trailing twelve-month  sales.The thesis on Bausch & Lomb Corp.  contends that the company is positioned for a robust upside ahead. Operating in three key segments; vision care , surgical equipment and consumables, and medications for eye conditions, BLCO leads worldwide in eye care. Bausch Health , the former parent company of BLCO, still owns an 88% market share. Hence, margin constraints resulting from large overhead expenses have impeded the stock performance despite its relatively strong market position.Disclosure: None. This article was originally published at Insider Monkey.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0b8JRfalk0QB7sySsbGkBg--~B/aD02OTM7dz0xMjE4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d7f0842ea5441613208a6bed96bbc5a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0b8JRfalk0QB7sySsbGkBg--~B/aD02OTM7dz0xMjE4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d7f0842ea5441613208a6bed96bbc5a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bausch-lomb-corporation-blco-bull-193143859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","BK4007","BLCO","BHC","TTM","BK4523","BK4099"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bauschhealth.com","stockEarnings":[{"period":"1week","weight":-0.0435},{"period":"1month","weight":-0.0879},{"period":"3month","weight":-0.0697},{"period":"6month","weight":0.0985},{"period":"1year","weight":0.0013},{"period":"ytd","weight":-0.0686}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.071905},{"month":2,"riseRate":0.642857,"avgChangeRate":0.039653},{"month":3,"riseRate":0.5,"avgChangeRate":-0.062435},{"month":4,"riseRate":0.642857,"avgChangeRate":0.010021},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.013304},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.002565},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.009218},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.003486},{"month":9,"riseRate":0.571429,"avgChangeRate":0.022231},{"month":10,"riseRate":0.6,"avgChangeRate":-0.048396},{"month":11,"riseRate":0.6,"avgChangeRate":0.047657},{"month":12,"riseRate":0.666667,"avgChangeRate":0.035688}],"exchange":"NYSE","name":"Bausch Health Companies Inc","nameEN":"Bausch Health Companies Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bausch Health Companies Inc(BHC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bausch Health Companies Inc(BHC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bausch Health Companies Inc,BHC,Bausch Health Companies Inc股票,Bausch Health Companies Inc股票老虎,Bausch Health Companies Inc股票老虎国际,Bausch Health Companies Inc行情,Bausch Health Companies Inc股票行情,Bausch Health Companies Inc股价,Bausch Health Companies Inc股市,Bausch Health Companies Inc股票价格,Bausch Health Companies Inc股票交易,Bausch Health Companies Inc股票购买,Bausch Health Companies Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bausch Health Companies Inc(BHC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bausch Health Companies Inc(BHC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction